| Description |
Lavoltidine (Loxtidine) is an an orally active, irreversible and highly potent histamine H2-receptor antagonist. Lavoltidine strongly inhibits gastric acid secretion and also induces hypergastrinemia[1].
|
| Related Catalog |
|
| Target |
H2 Receptor
|
| In Vivo |
Lavoltidine (Loxtidine; 0.5 g/L; orally (drinking water); changed weekly; for 3 months) shows partial suppression of both gastric acid secretion and progression to neoplasia. Lavoltidine inhibits gastric atrophy, hyperplasia, and dysplasia in H felis-infected INS-GAS mice[1]. Lavoltidine treatment for 6 months inhibits gastric tumors in H felis-infected INS-GAS mice[1]. Animal Model: Male hypergastrinemic mice (INS-GAS mice) infected with Helicobacter felis[1] Dosage: 0.5 g/L Administration: Orally (drinking water); changed weekly; for 3 months Result: Showed partial suppression of both gastric acid secretion and progression to neoplasia.
|
| References |
[1]. Takaishi S, et al. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.
|
